Sorrento Therapeutics IncOver The Counter Market:SRNE
- LAST PRICE0.0035
- TODAY'S CHANGE (%)-0.0003 (-7.8947%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0035 / 0.0038
- Day Range
- 52 Week Range
- Volume187,738
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SRNE |
|---|---|---|
| 09:32 ET | 18079 | 0.004 |
| 09:37 ET | 22970 | 0.0035 |
| 09:39 ET | 3143 | 0.0035 |
| 09:42 ET | 1325 | 0.0045 |
| 09:51 ET | 1000 | 0.0045 |
| 10:02 ET | 2205 | 0.0035 |
| 10:24 ET | 1000 | 0.0045 |
| 11:00 ET | 618 | 0.0045 |
| 11:21 ET | 33000 | 0.0035 |
| 11:39 ET | 100 | 0.0046 |
| 12:01 ET | 1600 | 0.0046 |
| 12:51 ET | 600 | 0.0036 |
| 12:55 ET | 100 | 0.0036 |
| 01:02 ET | 1000 | 0.0046 |
| 01:13 ET | 500 | 0.0036 |
| 01:38 ET | 200 | 0.0046 |
| 01:49 ET | 86900 | 0.0031 |
| 02:12 ET | 2000 | 0.0031 |
| 02:34 ET | 5000 | 0.0031 |
| 02:39 ET | 2099 | 0.0032 |
| 02:43 ET | 2790 | 0.0032 |
| 03:17 ET | 136 | 0.0035 |
| 03:53 ET | 959 | 0.0035 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sorrento Therapeutics Inc | 2.1M | 0.0x | --- |
MEI Pharma Inc | 20.1M | -0.4x | --- |
Molecular Templates Inc | 4.0M | -0.2x | --- |
Centogene NV | 3.6M | -0.1x | --- |
Bioqual Inc | 60.4M | 126.2x | -25.28% |
RVL Pharmaceuticals PLC | 110.0 | 0.0x | --- |
Company Information
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Contact Information
- Headquarters
- 4955 Directors PlaceSAN DIEGO, CA, United States 92121
- Phone
- 858-203-4100
- Fax
- 858-203-4028
Executives
- Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
- Henry Ji
- Lead Independent Director
- Dorman Followwill
- Director
- Kim Janda
- Director
- Jaisim Shah
- Independent Director
- David Lemus
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1M |
|---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Sorrento Therapeutics Inc does not pay a dividend. | |
Beta | 1.79 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
